Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Entrada Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2915.18%, while the net margin is -2734.45%. These profitability ratios, combined with a Return on Equity (ROE) of -27.11%, provide a clear picture of how effectively TRDA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TRDA competes directly with industry leaders such as ABSI and DMAC. With a market capitalization of $446.59M, it holds a significant position in the sector. When comparing efficiency, TRDA's gross margin of 100.00% stands against ABSI's 100.00% and DMAC's N/A. Such benchmarking helps identify whether Entrada Therapeutics Inc is trading at a premium or discount relative to its financial performance.
